Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $7.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on Atossa Therapeutics’ strategic advancements in the development of Z-endoxifen for breast cancer risk reduction. The company has requested a Type C meeting with the FDA to explore an accelerated regulatory pathway, which could potentially shorten the approval process and reduce trial costs. This proactive approach aims to streamline the drug’s path to market by addressing complex regulatory questions early on.
Moreover, Z-endoxifen presents significant market potential due to its advantages over existing therapies like tamoxifen. It offers equivalent anti-estrogen activity with fewer adverse events and a pharmacokinetic profile that avoids the CYP2D6 metabolic pathway, ensuring more consistent drug levels. These factors, combined with the drug’s faster onset of action, position Z-endoxifen as a promising option to meet the high unmet needs in breast cancer treatment, thus supporting the Buy rating.